HER2 Support Group Forums - View Single Post - Mixed reviews on scans while on tdm-1

schoonder · 12-13-2010, 12:32 PM

Yes, third arm of Marianne trial, T-DM1 plus Pertuzumab could be a very effective treatment.
Immunogen Inc reported on T-DM1 Plus Pertuzumab for First-Line HER2+ mBC. The data reported today from SABCS are from a Phase Ib/II clinical trial conducted by Roche to assess T-DM1 used in combination with pertuzumab to treat HER2+ mBC. The study enrolled 21 patients who had not received prior systemic anticancer therapy for metastatic disease. Among these patients, 57.1% had a confirmed objective response to treatment with T-DM1 plus pertuzumab.

All of these patients had received anticancer agents prior to their development of metastatic disease (e.g., as adjuvant therapy). Eighty-six percent (86%) of these patients had received Herceptin® (trastuzumab), 71% had received a taxane, and 62% had received an anthracycline before being diagnosed with metastatic disease.

12-13-2010, 12:32 PM	#11
schoonder Senior Member Join Date: Jul 2008 Posts: 186	Re: Mixed reviews on scans while on tdm-1 Yes, third arm of Marianne trial, T-DM1 plus Pertuzumab could be a very effective treatment. Immunogen Inc reported on T-DM1 Plus Pertuzumab for First-Line HER2+ mBC. The data reported today from SABCS are from a Phase Ib/II clinical trial conducted by Roche to assess T-DM1 used in combination with pertuzumab to treat HER2+ mBC. The study enrolled 21 patients who had not received prior systemic anticancer therapy for metastatic disease. Among these patients, 57.1% had a confirmed objective response to treatment with T-DM1 plus pertuzumab. All of these patients had received anticancer agents prior to their development of metastatic disease (e.g., as adjuvant therapy). Eighty-six percent (86%) of these patients had received Herceptin® (trastuzumab), 71% had received a taxane, and 62% had received an anthracycline before being diagnosed with metastatic disease.